lan.png
EN
search.png
{$ImageUrl,alt}
Blog
home.png Home>Blog
更换7.jpg
2024.12.03
Comprehensive Analysis of Liposome Types: Diversified Solutions for Vaccine Delivery
Comprehensive Analysis of Liposome Types: Diversified Solutions for Vaccine DeliveryLiposomes, as crucial carriers for vaccine delivery, possess unique structural and functional characteristics that enable them to meet the complex needs of various vaccines. Fr...
更换6.jpg
2024.12.03
Breakthrough of Liposome Technology in Cancer Therapy: FDA Approval of Irinotecan Liposome for First-Line Treatment of Metastatic Pancreatic Adenocarcinoma
Breakthrough of Liposome Technology in Cancer Therapy: FDA Approval of Irinotecan Liposome for First-Line Treatment of Metastatic Pancreatic Adenocarcinoma In May 2024, the U.S. Food and Drug Administration (FDA) announced the approval of irinotecan lipos...
20241212160900639.png
2024.12.03
mRNA Vaccines and Lipid Nanoparticle Lyophilization Technology: Breakthroughs in Innovative Delivery Systems in Vaccine Development
mRNA Vaccines and Lipid Nanoparticle Lyophilization Technology: Breakthroughs in Innovative Delivery Systems in Vaccine Development Driven by the COVID-19 pandemic, mRNA vaccines and lipid nanoparticle (LNP) delivery systems have become key technologies i...
LNP-Encapsulation.png
2025-02-18
Litchlab: Advancing mRNA Drug Delivery with Cutting-Edge Lipid Technology
The emergence of mRNA therapeutics has transformed modern medicine, offering groundbreaking treatments for infectious diseases, cancer, genetic disorders, and protein replacement therapy. However, efficient delivery of mRNA remains a critical challenge due to ...
更换11.jpg
2025-02-17
Litchlab: Advancing RNA Drug Delivery with Liposomal Technology
RNA-based therapeutics, including siRNA, mRNA, and ASO, are rapidly transforming precision medicine, offering promising treatments for cancer, genetic disorders, infectious diseases, and vaccines. However, challenges such as RNA instability, susceptibility to ...
更换25.jpg
2025-02-14
Litchlab: Advancing RNA Therapeutics with Cutting-Edge Liposomal Technology
 RNA-based therapies, such as siRNA, mRNA, and ASOs, have emerged as groundbreaking treatments for genetic disorders, cancers, and infectious diseases. However, the delivery challenge remains a major barrier—naked RNA molecules are highly unstable, easily...
更换10.jpg
2025-02-12
Litchlab Expands Advanced Lipid Synthesis & Modification Capabilities to Drive Next-Gen Drug Delivery
Litchlab, a global leader in lipid-based drug delivery solutions, has announced the expansion of its advanced lipid synthesis and modification capabilities. With cutting-edge technologies and an innovative approach, Litchlab provides customized lipid solutions...
更换29.jpg
2025-02-11
FDA Approves Onivyde Combination Therapy: Litchlab Advances Liposomal Precision Oncology
The U.S. Food and Drug Administration (FDA) has approved liposomal irinotecan (Onivyde) in combination with oxaliplatin, fluorouracil, and leucovorin (NALIRIFOX regimen) as a first-line treatment for metastatic pancreatic adenocarcinoma. This landmark approval...
更换16.jpg
2025-02-10
Litchlab Advances PEGylation Technology to Enhance Drug Delivery and Biocompatibility
In modern biopharmaceuticals, PEGylation has emerged as a key strategy for optimizing drug delivery, improving therapeutic efficacy, and prolonging drug half-life. As a global leader in CDMO (Contract Development and Manufacturing Organization) services, Litch...
上一页 56789 下一页